Genmab | GEN - Interest Expense On Debt


Genmab reported DKK139M in Interest Expense on Debt for its fiscal quarter ending in June of 2026.





Interest Expense On Debt Change Date
Agios Pharmaceuticals USD 1.11B 76.57M Jun/2026
Amarin USD 3K 5K Dec/2024
Amgen USD 95.64B 94.98B Jun/2026
argenx SE USD 1000K 172K Mar/2026
AstraZeneca USD 340M 144M Jun/2026
Bayer EUR 675M 87M Dec/2025
BioMarin Pharmaceutical USD 63.29M 48.34M Jun/2026
Demant DKK 424M 26M Jun/2026
Exelixis USD 23.4M 3.9M Sep/2023
Fresenius Medical Care EUR 83M 4M Jun/2026
Genmab DKK 139M 129M Jun/2026
GlaxoSmithKline GBP 121M 46M Jun/2026
GN Store Nord DKK 286M 10M Jun/2026
GRIFOLS EUR 141.43M 61.28M Jun/2025
Hikma Pharmaceutical USD 67M 47M Dec/2025
Insmed USD 18.84M 1.24M Jun/2026
Lakefront Biotherapeutics EUR 1.72M 940K Sep/2025
Lonza CHF 84M 14M Jun/2025
Merck EUR 137M 33M Jun/2026
Novartis USD 462M 119M Jun/2026
Regeneron Pharmaceuticals USD 11M 1.9M Jun/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR 287M 109M Jun/2026
UCB EUR 49M 29M Dec/2025